Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

QURE.US Logo

QURE.US - Current Price

$21.41

Company Information

▼
Company Name
Uniqure NV
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: NL0010696654
CIK: 0001590560
CUSIP: N90064101
Currency: USD
Full Time Employees: 209
Phone: 31 20 240 6000
Website: https://www.uniqure.com
Fiscal Year End: December
IPO Date: Jun 20, 2007
Description:

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Address:

Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP

Directors & Officers

▼
Name Title Year Born
Mr. Matthew Craig Kapusta CPA CEO & Executive Director 1972
Mr. Christian Klemt CFO, Principal Financial Officer & GM of Amsterdam Site 1973
Dr. Jeannette Potts J.D., Ph.D. Chief Legal & Compliance Officer and Corporate Secretary 1962
Dr. Walid Abi-Saab M.D. Chief Medical Officer 1965
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany NA
Dr. Amin Abujoub Ph.D. Chief Technical Operations Officer NA
Mr. Richard Porter Ph.D. Chief Business & Scientific Officer 1968
Ms. Chiara Elizabeth Russo Senior Director of Investor Relations NA
Dr. Tamara Tugal Ph.D., MBA Business Development Director NA
Ms. Erin Boyer Chief People & Culture Officer NA

Shares Statistics

▼
Shares Outstanding: 62.29M
Shares Float: 45.99M
% Insiders: 532.60%
% Institutions: 9,270.20%
Short % Float: 14.56%

Valuation Metrics

▼
Enterprise Value: $949.13M
Trailing P/E: 0.00
Forward P/E: 27.93

Financial Highlights

▼
Market Cap: $1.44B
EBITDA: $-154.37M
PEG Ratio: $0.00
Book Value: $3.68
Earnings/Share: $-4.40
Profit Margin: 0.00%
Operating Margin: -1,329.72%
ROA (TTM): -13.89%
ROE (TTM): -165.27%
Revenue (TTM): $15.75M
Revenue/Share (TTM): $0.29
Earnings Growth (YOY): -18.20%
Revenue Growth (YOY): 61.80%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 -0.91 N/A 10,000.00%
Sep 30, 2025 -1.38 -0.91 N/A -5,164.84%
Jun 30, 2025 -0.69 -0.89 N/A 2,247.19%
Mar 31, 2025 -0.73 -0.89 N/A 1,788.33%
Dec 31, 2024 -1.44 -0.52 N/A -17,882.01%
Sep 30, 2024 -0.91 -1.02 N/A 1,078.43%
Jun 30, 2024 -1.16 -1.25 N/A 720.00%
Mar 31, 2024 -1.36 -1.28 N/A -625.00%
Dec 31, 2023 -1.53 -1.46 N/A -479.45%
Sep 30, 2023 -1.88 -0.85 N/A -12,117.65%
Jun 30, 2023 -1.44 2.05 N/A -17,024.39%
Mar 31, 2023 -1.63 -0.95 N/A -7,157.89%
Dec 31, 2022 0.15 -0.89 N/A 11,685.39%
Sep 30, 2022 -1.02 -1.16 N/A 1,206.90%
Jun 30, 2022 -0.84 -1.00 N/A 1,600.00%
Mar 31, 2022 -1.00 -0.93 N/A -752.69%
Dec 31, 2021 0.17 -0.81 N/A 12,098.77%
Sep 30, 2021 -0.79 -1.05 N/A 2,476.19%
Jun 30, 2021 8.51 2.96 N/A 18,750.00%
Mar 31, 2021 -0.91 -0.88 N/A -340.91%
Dec 31, 2020 -0.01 1.52 N/A -10,065.79%
Sep 30, 2020 -1.21 1.65 N/A -17,333.33%
Jun 30, 2020 -0.96 -0.67 N/A -4,328.36%
Mar 31, 2020 -0.63 -0.84 N/A 2,500.00%
Dec 31, 2019 -0.96 -0.73 N/A -3,150.68%
Sep 30, 2019 -0.58 -0.81 N/A 2,839.51%
Jun 30, 2019 -0.83 -0.75 N/A -1,066.67%
Mar 31, 2019 -0.74 -0.71 N/A -422.54%
Dec 31, 2018 -0.59 -0.66 N/A 1,060.61%
Sep 30, 2018 -0.59 -0.62 N/A 483.87%
Jun 30, 2018 -0.57 -0.61 N/A 655.74%
Mar 31, 2018 -0.59 -0.74 N/A 2,027.03%
Dec 31, 2017 -0.91 -0.77 N/A -1,818.18%
Sep 30, 2017 -0.40 -0.63 N/A 3,650.79%
Jun 30, 2017 -0.75 -0.67 N/A -1,194.03%
Mar 31, 2017 -0.75 -0.60 N/A -2,500.00%
Dec 31, 2016 -0.51 -0.56 N/A 892.86%
Sep 30, 2016 -0.54 -0.79 N/A 3,164.56%
Jun 30, 2016 -0.77 -0.78 N/A 128.21%
Mar 31, 2016 -0.83 -0.73 N/A -1,369.86%
Sep 30, 2015 -1.08 -0.58 N/A -8,620.69%
Jun 30, 2015 -0.87 0.49 N/A -27,755.10%
Mar 31, 2015 -0.77 -0.62 N/A -2,419.35%
Sep 30, 2014 -0.68 -0.64 N/A -625.00%
Jun 30, 2014 -0.70 -0.56 N/A -2,500.00%
Mar 31, 2014 -0.71 -0.45 N/A -5,777.78%
Dec 31, 2013 -0.49 N/A N/A N/A

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $158.93M $N/A $556.54M $563.29M $-6.75M
2023-12-31 $241.36M $N/A $831.69M $624.02M $207.67M
2022-12-31 $228.01M $N/A $704.96M $228.96M $476.01M
2021-12-31 $556.26M $N/A $809.18M $213.40M $595.78M
2020-12-31 $244.93M $N/A $340.40M $96.49M $243.91M
2019-12-31 $377.79M $N/A $448.63M $125.57M $323.06M
2018-12-31 $234.90M $N/A $273.91M $94.30M $179.61M
2017-12-31 $159.37M $N/A $208.88M $118.93M $89.95M
2016-12-31 $132.50M $N/A $190.27M $126.63M $63.63M
2015-12-31 $222.52M $N/A $264.69M $134.06M $130.63M
2014-12-31 $64.71M $N/A $116.48M $64.09M $52.39M
2013-12-31 $32.88M $N/A $53.81M $46.13M $7.68M
2012-12-31 $347.82K $N/A $7.36M $7.95M $-592.48K
2011-12-31 $1.43M $N/A $7.52M $10.88M $-3.36M
2010-12-31 $23.75M $N/A $30.19M $12.03M $18.17M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Sep 26, 2025 N/A N/A N/A N/A N/A N/A
Sep 24, 2025 N/A N/A N/A N/A N/A N/A
Sep 24, 2025 N/A N/A N/A N/A N/A N/A
Jun 27, 2025 N/A N/A N/A N/A N/A N/A
Jun 20, 2025 N/A N/A N/A N/A N/A N/A
Jun 20, 2025 N/A N/A N/A N/A N/A N/A
Jun 20, 2025 N/A N/A N/A N/A N/A N/A
Jun 20, 2025 N/A N/A N/A N/A N/A N/A
Jun 20, 2025 N/A N/A N/A N/A N/A N/A
Jun 20, 2025 N/A N/A N/A N/A N/A N/A
Jun 20, 2025 N/A N/A N/A N/A N/A N/A
Jun 16, 2025 N/A N/A N/A N/A N/A N/A
Mar 04, 2025 N/A N/A N/A N/A N/A N/A
Mar 04, 2025 N/A N/A N/A N/A N/A N/A
Mar 04, 2025 N/A N/A N/A N/A N/A N/A
Feb 27, 2025 N/A N/A N/A N/A N/A N/A
Feb 27, 2025 N/A N/A N/A N/A N/A N/A
Feb 25, 2025 N/A N/A N/A N/A N/A N/A
Feb 25, 2025 N/A N/A N/A N/A N/A N/A
Dec 09, 2024 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist